Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Barbara A Konkle, Amy Shapiro, Doris Quon, Janice Staber, Takashi Suzuki, MD PhD, Stacey Poloskey, Kara Rice, Suresh Katragadda, Dan Rudin, Joachim Fruebis

Blood (2018) 132 (Supplement 1): 636.

https://doi.org/10.1182/blood-2018-99-113575

Published: 2018

Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD

Blood (2018) 132 (Supplement 1): 1186.

https://doi.org/10.1182/blood-2018-99-115792

Published: 2018

Journal Articles

Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B- Interim Result of Post Marketing Surveillance Study -

Takashi Suzuki, MD, PhD, Katsuyuki Fukutake, MD, PhD, Kagehiro Amano, MD, PhD, Hideji Hanabusa, MD, Masashi Taki, MD, PhD, Tadashi Matsushita, MD, PhD, Midori Shima, MD, PhD, Michio Sakai, MD, PhD, Masahiro Iizuka, Yoshiyuki Shibasaki

Blood (2012) 120 (21): 3378.

https://doi.org/10.1182/blood.V120.21.3378.3378

Published: 2012

Journal Articles

Severe Factor V Deficiency Caused by a Novel Compound Heterozygous Mutation: Factor V G1617V and 1-Bp Insertion

Keiko Shinozawa, PhD, Yuri Okimoto, MD, PhD, Kagehiro Amano, MD, PhD, Harumi Kakuda, MD, PhD, Takeshi Hagiwara, MD, PhD, Takashi Suzuki, MD, PhD, Hiroshi Inaba, PhD, Katsuyuki Fukutake, MD, PhD

Blood (2011) 118 (21): 2268.

https://doi.org/10.1182/blood.V118.21.2268.2268

Published: 2011

Journal Articles

The Severity of Bleeding Tendency in 5 Patients with Factor V Deficiency Due to Distinct Kinds of Factor V Mutations.

Keiko Shinozawa, PhD, Kagehiro Amano, MD, PhD, Takashi Suzuki, MD, PhD, Hiroshi Inaba, PhD, Katsuyuki Fukutake, MD, PhD

Blood (2007) 110 (11): 1764.

https://doi.org/10.1182/blood.V110.11.1764.1764

Published: 2007

NARROW

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B- Interim Result of Post Marketing Surveillance Study -

Severe Factor V Deficiency Caused by a Novel Compound Heterozygous Mutation: Factor V G1617V and 1-Bp Insertion

The Severity of Bleeding Tendency in 5 Patients with Factor V Deficiency Due to Distinct Kinds of Factor V Mutations.

Email alerts

ASH Publications

American Society of Hematology

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B- Interim Result of Post Marketing Surveillance Study -

Severe Factor V Deficiency Caused by a Novel Compound Heterozygous Mutation: Factor V G1617V and 1-Bp Insertion

The Severity of Bleeding Tendency in 5 Patients with Factor V Deficiency Due to Distinct Kinds of Factor V Mutations.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only